Published in Medical Letter on the CDC and FDA, April 24th, 2005
The 250-person sales team, led by 25 district managers, is calling on primary care physicians who account for 40% of fluoroquinolone prescriptions written for respiratory tract infections across the United States. As with the initial 100 sales representatives in place at launch, the newest hires have extensive pharmaceutical experience, an average of 5 years, and over two-thirds have sold anti-infectives previously.
The sales force is currently concentrating on the commercialization of FACTIVE...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.